

## **CORRECTION**

In the article “Ultra-Low-Dose Buprenorphine as a Time-Limited Treatment for Severe Suicidal Ideation: A Randomized Controlled Trial” by Yoram Yovell, M.D., Ph.D., et al. (doi: 10.1176/appi.ajp.2015.15040535), published online on Dec. 18, 2015, the financial disclosures were omitted. The disclosures paragraph should read, “Dr. Yovell reports being listed as an inventor on a patent application for the use of low-dose buprenorphine for suicidality; he has assigned his rights in the patent to the University of Haifa but will share a percentage of any royalties that may be received by the university. The other authors report no financial relationships with commercial interests.” This correction was made and the article was re-posted on January 11, 2016.